

REMARKS

Claims 1-17 are pending in the present application.

Entry of the above amendments is earnestly solicited. An early and favorable first action on the merits is earnestly requested.

Should there be any matters that need to be resolved in the present application, the Examiner is respectfully requested to contact the undersigned at the telephone number listed below.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned "VERSION WITH MARKINGS TO SHOW CHANGES MADE."

The Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 25-0120 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17.

Respectfully submitted,

YOUNG & THOMPSON



Benoit Castel, Reg. No. 35,041

745 South 23rd Street
Arlington, VA 22202
Telephone (703) 521-2297

BC/ma
Attachments

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE ABSTRACT OF THE DISCLOSURE:

The Abstract of the Disclosure has been amended as follows:

Abstract of the Disclosure

Disclosed is an intraluminal device, suitable for implantation in a body. ~~Said~~The intraluminal device is provided with a coating which comprises: 50-97% heparan sulfate; 1-20% laminin; 0.2-15% type IV collagen. Furthermore a coating is disclosed, which coating is suitable for the above mentioned device, as well as a method for preparing such device, comprising the steps of: providing a intraluminal device for implantation in a body; preparing a composition, comprising, in about 50 mg/ml solvent: 50-97% heparan sulfate; 1-20% laminin; 0.2-15% type IV collagen; the solvent being a suitable buffer or water; dipping the intraluminal device in the composition; and drying the dipped intraluminal device.

IN THE CLAIMS:

The claims have been amended as follows:

3. (Amended) Intraluminal device according to claim 1 ~~or 2~~, characterised in that the coating comprises entactin and nidogen.

4. (Amended) Intraluminal device according to claim 1 ~~3~~, characterised in that the coating furthermore comprises a growth factor.

6. (Amended) Intraluminal device according ~~one or more of the preceding claims~~, to claim 1, characterised in that the coating comprises an antibiotic.

8. (Amended) Intraluminal device according to ~~one or more of the preceding claims~~, claim 1, characterised in that the coating comprises vitronectine.

9. (Amended) Intraluminal device according to ~~one or more of the preceding claims~~, claim 1, characterised in that the coating comprises:

85-95% heparan sulfate;

5-6% laminin,;

3-4% type IV collagen;

0.5-1.5% entactin and nidogen;

0.001-1% growth factors;

0.001-1% antibiotic.

10. (Amended) Intraluminal device according to ~~one or more of the preceding claims~~, claim 1, characterised in that the prosthesis comprises a stent or a graft.

11. (Amended) Coating suitable for a intraluminal device according to ~~one or more of the preceding claims 1-10~~, claim 1.

12. (Amended) Method for preparing a intraluminal device according to ~~one or more of the claims 1-10~~, claim 1, comprising the steps of:

- providing a intraluminal device for implantation in a body;

- preparing a composition, comprising, in about 50 mg/ml solvent:

 - 50-97% heparan sulfate;

 - 1-20% laminin;

 - 0.2-15% type IV collagen;

 - the solvent being a suitable buffer or water;

- dipping the intraluminal device in the composition; and
- drying the dipped intraluminal device.

14. (Amended) Method according to claim ~~12 or 13~~, characterised in that the composition furthermore comprises a growth factor, chosen from the group consisting of bFGF, IGF, TGF- β and VEGF.

15. (Amended) Method according to ~~one or more of claims 12-14~~, claim 12, characterised in that the composition comprises an antibiotic.

16. (Amended) Method according to ~~one or more of claims 12-15~~, claim 12, characterised in that the composition comprises vitronectin.

17. (Amended) Method according to ~~one or more of the claims 12-16~~, claim 12, characterised in that the composition comprises:

85-95% heparan sulfate;
5-6% laminin;
3-4% type IV collagen;
0.5-1.5% entactin and nidogen;
0.001-1% growth factors;
0.001-1% antibiotic.